DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2020 年 11 月 02 日 1:00 下午 - 2020 年 11 月 04 日 4:25 下午

(Central Europe Standard Time)

4051 Basel, Switzerland

Pharmacovigilance Strategies Workshop

讲演嘉宾

Wendy  Huisman, PharmD

Wendy Huisman, PharmD

Director, Vigifit, Netherlands

Over the past 25 years Wendy has been dedicated to pharmacovigilance. She has broad experience as EU QPPV for generic and innovative products in complex companies. She also has wealth of experience in lobbying and networking in trade associations/working groups. In her current role, Wendy provides pharmacovigilance support to Pharmaceutical Industry and SMEs (startups). She enjoys setting up the PV system and supports in the development of the PSMF with associated documents. Since 2020 Wendy is a trained professional in Transactional Analysis (TA). TA is a theory of human personality and social behavior. TA gives a wealth of options to work with challenges and changes in organisational and personal development.

Shahin  Kauser

Shahin Kauser

Leading Senior Scientific Assessor, MHRA, United Kingdom

Shahin Kauser also has a Certificate in Pharmacoepidemiology & Pharmacovigilance from the London School of Hygiene and Tropical Medicine. Shahin is a Leading Senior Scientific Assessor and joined the MHRA Agency (former MCA) in 2001. She has extensive experience of the ‘life-cycle’ of pharmacovigilance both nationally and in Europe. Her current portfolio includes monitoring the post-marketing safety of medicines in various therapeutic areas including blood disorders, multiple myeloma and malignant melanoma. Shahin has expertise in assessing benefit/risk, PSURs, safety Variations and risk management plans, additional risk minimisation measures and assessing their effectiveness.

Maarten  Lagendijk, MSc

Maarten Lagendijk, MSc

Deputy EU QPPV, MSD, Netherlands

Maarten Lagendijk is currently Deputy EU QPPV at MSD. Previously he has held different positions in pharmacovigilance at the Medicines Evaluation Board (MEB), the Dutch Regulatory Authority, with increasing responsibilities. With over 15 years of experience in pharmacovigilance, Maarten has a good understanding of all different aspects of safety and risk evaluation of medicines in a broad range of therapeutic areas, most notably in oncology and hematology, as well as in immunology and pulmonology. Through the years he has also focused on developments around risk communication and additional risk minimisation, as well as the evolution of risk management and efforts to streamline and harmonise risk management plans.

Bianca  Mulder, PharmD, MPharm, MSc

Bianca Mulder, PharmD, MPharm, MSc

Pharmacovigilance Assessor, Medicines Evaluation Board, Netherlands

Bianca Mulder is a pharmacist with a PhD in pharmacoepidemiology. Her research focused on the use of medication during pregnancy and the development of atopic diseases in children. She worked briefly in a pharmacovigilance position at a pharmaceutical company before she started working as a pharmacovigilance assessor at the Dutch national agency (MEB) in 2016.

Elena  Popa, MPharm

Elena Popa, MPharm

Regulatory Policy and Innovation Lead, Bayer, Switzerland

Elena is a pharmacist by training with a master in drug safety and pharmacovigilance. She joined Bayer as a Regulatory Policy & Intelligence Lead and provides direction and development of Regulatory Policy & Intelligence activities supporting Bayer’s pipeline and strategies, with a particular emphasis on the regulatory use and acceptance of RWD/RWE in drug development. Before joining Bayer, Elena was a Senior Manager, Scientific Programmes at Drug Information Association and engaged annually with over 500 stakeholders and volunteers from the entire healthcare ecosystem. In her free time, Elena is passionate about traveling, visiting art museums, painting and watching Formula 1 (#essereFerrari).

Francoise  Sillan, MD

Francoise Sillan, MD

EU1 UK QPPV, Ipsen, France

Françoise is a medical doctor as background, working in Pharmacovigilance for more than 30 years in big Pharmaceutical companies with different managerial roles, interactions with Health Authorities, and coordination of international networks of Pharmacovigilance. She has spent 15 Years on Vaccine Pharmacovigilance where she contributed to the development of standards definitions and methods through CIOMS WHO working groups on vaccine safety. Within the EFPIA Pharmacovigilance expert group, she analysed the influence of EU pharmacovigilance regulations outside Europe and of non EU regulations on the EUQPPV role.

Mette  Stockner, MD

Mette Stockner, MD

Senior Pharmacovigilance Director, Savara ApS, Denmark

Mette is a Medical Doctor by training with more than 20 years of hands on experience within Headquarter pharmacovigilance in small to large sized pharmaceutical companies and has worked in the USA, Switzerland and in Denmark. She has been heading up global operational and scientific safety functions and been the Qualified Person for Pharmacovigilance and Deputy QPPV and Head of PV Compliance. Currently overseeing the safety function in a small company working within rare diseases.

Willemijn  van der Spuij, MSc

Willemijn van der Spuij, MSc

Executive Director, WorldWide Patient Safety International, Europe, Switzerland

Willemijn is the Executive Director Europe in the WorldWide Patient Safety Organisation in Bristol Myers Squibb. She is responsible for Patient Safety in the European region, including the Balkans, Baltics and distributor markets. Prior to this role she was responsible for the European markets, PV Intelligence & International Operations including the PSMF as well as Training and Outsourcing activities. Willemijn holds a Nursing Degree from the Netherlands, a BA (Hons) in Sociology from Goldsmiths college, University of London, UK and an MSc in Pharmacovigilance from the University of Hertfordshire, UK. Willemijn is co-chair of the EFPIA Pharmacovigilance Expert Working Group and Chair of the EFPIA International Pharmacovigilance Group.

James  Whitehead, MBA, MSc

James Whitehead, MBA, MSc

Senior Director, Device & Digital Safety, AstraZeneca, United Kingdom

James Whitehead is the Senior Director, Device & Digital Safety at AstraZeneca working within Global Patient Safety, having started his career with AZ as a Pharmacovigilance Scientist in Oncology. Since graduating with a BSc in Psychology from the University of Leicester, James has held positions at CROs, Pharmaceutical Companies and Consulting Practises with a focus on Signal and Risk Management. That passion for Signal and Risk Management culminated in a MSc in Pharmacovigilance from the University of Hertfordshire, James is now a Visiting Lecturer on the course. Recently, James studied for an MBA and focused this project on innovation and digital transformation within Patient Safety.

Anja  Van Haren, MSc

Anja Van Haren, MSc

Eudravigilance coordinator, Medicines Evaluation Board (MEB), Netherlands

Anja van Haren holds a Master in Health Policy and Management from the Erasmus University in Rotterdam. Her career at the Medicines Evaluation Board (MEB) in the Netherlands started in 1998 as a Pharmacovigilance assessor. Since 2004 she has been responsible for technical and procedural aspects of expedited Adverse Drug Reaction reporting in pharmacovigilance. In her current position at the MEB as EudraVigilance Coordinator the focus of her work is on ADR reports, signal detection and signal management. Anja is co-chair of the EudraVigilance Expert Working Group, co-chair of the Pharmacovigilance Business Team and representative of the EU in the ICH E2B(R3) and ICH E2D(R1) Expert Working Groups.

Clare  Lavery, MSc

Clare Lavery, MSc

Pharmacovigilance Excellence Principal, AstraZeneca, United Kingdom

Clare works in the QPPV Office and has been the AstraZeneca PSMF Coordinator for the past seven years. Other Pharmacovigilance related activities include EudraVigilance access management and PRAC monitoring. Prior to joining AstraZeneca Clare enjoyed an extensive Regulatory Affairs career for companies such as Boehringer Ingelheim and Johnson & Johnson.

Elspeth  McIntosh, MBA, RN

Elspeth McIntosh, MBA, RN

Director, Castle Pharmacovigilance Ltd, United Kingdom

Elspeth McIntosh began her career in the pharmaceutical industry in 1993, initially working in clinical research, before moving into Pharmacovigilance. She has extensive experience of all aspects of pharmacovigilance and has been a small company QPPV since 1999, dealing with innovative, generic and biotech/biological products. Elspeth set up Castle Pharmacovigilance in 2009 and post Brexit she is a UK QPPV and UK National Contact Person for several small pharma companies and provides general PV support to a wide range of pharma companies.

Dionne  Usher

Dionne Usher

Associate Director, Office of the EU QPPV, Merck Sharp & Dohme Limited, United Kingdom

Dionne works in the Office of the EU QPPV for MSD in the UK as the PSMF Owner. Interested in “all things PSMF” and other primary areas of support are EudraVigilance access management, PV Audits and Inspections and ad hoc EU QPPV Office projects and activities.

Magnus  Ysander, MD

Magnus Ysander, MD

EU & UK QPPV & Head Pharmacovigilance Excellence, AstraZeneca, Sweden

Magnus Ysander is the EU and UK QPPV for the AstraZeneca group of companies since 2015 and is based in Gothenburg, Sweden. He joined the company in 2002 and have had several specialist, oversight and line managerial roles within the AstraZeneca pharmacovigilance organisation. Magnus is a MD and has previously worked as a certified Orthopedic Surgeon. He is a member of EFPIA Pharmacovigilance Expert Group and the Program Committee for the DIA QPPV Forum.

Johan  Hellmér, MD, PhD

Johan Hellmér, MD, PhD

EUQPPV, Takeda Pharmaceuticals, Sweden

Elena  Prokofyeva, MD, PhD, MPH

Elena Prokofyeva, MD, PhD, MPH

Head of Drug Safety Unit, Department of Research & Development, DG PRE, Federal Agency for Medicines and Health Products (FAMHP), Belgium

Dr. Elena Prokofyeva is head of drug safety unit at the Department of Research & Development, DG PRE, the FAMHP, Brussels, Belgium. She represents Belgium within the CTFG safety subgroup. She initiated and led an update of the Q&A-RSI document within the CTFG. Dr. Prokofyeva holds a research doctorate from the University of Tuebingen, Germany, a Ph.D. and an M.D. from the Northern State Medical University, Arkhangelsk, Russia, and a Master of Public Health from the University of Umeå, Sweden. Harmonization of safety assessment across members of states in Europe, preparation for the implementation of a safety related part of clinical trial regulation, and safeguarding the safety of trial participants are main objectives of her work.

Sabine  Straus, MD, PhD, MSc

Sabine Straus, MD, PhD, MSc

Former PRAC Chair, Medicines Evaluation Board (MEB), Netherlands

Dr. Sabine Straus has been with the Medicines Evaluation Board (MEB) in the Netherlands since 1997, where she started as an Assessor Pharmacovigilance. Prior to working at the MEB she held different positions in the pharmaceutical industry, her last job as Medical Director at Searle Monsanto in the Netherlands. She was the Dutch member in the Pharmacovigilance Risk Assessment Committee (PRAC) from 2012 till 2018 and acted as PRAC chair from July 2018 till July 2024. She also holds a position as associate professor at the Erasmus Medical Center, department of Medical Informatics in Rotterdam. Her main research focus is on additional risk minimisation, pregnancy prevention programs, biologicals, signal detection and signal management.

Ulka  Campbell

Ulka Campbell

Senior Director, Epidemiology, Pfizer, United States

Ulka Campbell is the Head of Safety Surveillance Research at Pfizer, which designs and implements epidemiology research strategies to support risk management of the portfolio, including post-approval safety studies (PASS). She is an Adjunct Assistant Professor of Epidemiology at Columbia University School of Public Health, and teaches and has published on topics related to pharmacoepidemiology and causal inference. Ulka holds a PhD in epidemiology from Columbia University and an MPH in epidemiology from the University of Michigan.

Corinne  de Vries, PhD, MA, MSc

Corinne de Vries, PhD, MA, MSc

Head of Translational Sciences Office, European Medicines Agency, Netherlands

Corinne is a pharmacist and an epidemiologist (PhD) and has an MA in medical ethics and law. She has gained 20 years’ research experience in academia before making the move to the regulatory environment. Throughout her career, she has worked in multinational and multicultural environments, acquired scientific and regulatory expertise, communication, education and presentation skills, as well as a thorough understanding of project and budget management. She is an active member of the International Society for Pharmacoepidemiology with previous roles as Board member, VP Finance, and various committees. She is visiting professor of pharmacoepidemiology at the University of Bath in the UK.

Julia  Frese, MBA

Julia Frese, MBA

Department Manager Centre of Combination Products, TÜV SÜD , Germany

By education biomedical engineer with a Master degree in business administration. Julia gained experience in development, regulatory approval of combination devices and ATMP products. She was further involved in the development of standards for ATMP products. Currently Julia Frese is heading the division of Medical and Health Services at TÜV SÜD Japan and is responsible for the development of article 117 service within the organisation. She is further co-chair of the Team NB working group for article 117.

Andreas  Iwanowitsch

Andreas Iwanowitsch

Director Medical Affairs / Corporate PV, EU QPPV, STADA Arzneimittel AG , Germany

Andreas has a PhD in Chemistry and works in the pharmaceutical industry since 1996 in the fields clinical research, biostatistics and pharmacovigilance. In 2008 he joined STADA and became Head of Global Pharmacovigilance Unit and EU QPPV Backup in 2013.

Sergio  Ley-Acosta, MD

Sergio Ley-Acosta, MD

Global Head Portfolio Clinical Safety, Genentech, United States

Louise  Mawer

Louise Mawer

Director, Mirabilitas Ltd, United Kingdom

Louise Mawer, Director, Mirabilitas Ltd, is a GxP quality assurance auditor and trainer, with over twenty years’ experience in GCP, GLP and, more recently, GVP. A former UK Inspector for GCP and GLP, Louise spent seven years with the MHRA, before returning to the pharmaceutical industry in 2011 and establishing her own consultancy in 2013. Louise is Chair of the Quality Working Party of the European Forum for GCP (EFGCP) and a member of the Research Quality Association Research Practice Group. Louise has presented at national and international events, and developed training for GCP, GLP and GVP stakeholders and audit groups.

Jan  Petracek, MD, MSc

Jan Petracek, MD, MSc

CEO, Ivigee, Czech Republic

Jan is a passionate and visionary leader in the field of pharmacovigilance, with over 20 years of experience in the industry. He is the CEO of iVigee, a company that provides innovative and sustainable solutions for drug safety and risk management. He is also a Fellow of the International Society of Pharmacovigilance (FISoP), a Global Fellow in Medicines Development (GFMD), and a Qualified Person for Pharmacovigilance (QPPV). Jan has a proven track record of establishing, growing, and selling successful organizations, both for-profit and non-profit, in the pharmacovigilance sector. He has received multiple awards and recognitions, including the DIA Excellence in Service Award in 2018 and HM Queen's Award for International Trade in 2019.

Barbara  Reinhardt

Barbara Reinhardt

Associate Director | Global Patient Safety | Safety Science, Merck Healthcare KGaA, Germany

Barbara has more than 20 years of experience in global clinical trial management, started as CRA in a CRO, continued as Clinical Trial Manager and Project Manager in global development and worked in different companies in the pharma industry locally and abroad. In her current role as Safety Scientist Barbara has 10 years of experience in clinical trials safety management with knowledge of safety management procedures and safety reporting requirements.

Khaudeja  Bano, DrMed, MD, MS

Khaudeja Bano, DrMed, MD, MS

Vice President, Combination Product Quality, Amgen, United States

Dr. Bano is the Vice President of Combination product Quality at Amgen. She is a Physician, with a Masters in Clinical Research (UCSD), Pharmaceutical engineering Certification, a Database Administrator and a certified Project Management Professional. She is an Abbott President’s award winner, avid Toastmaster and a certified coach. Khaudeja has more than 25 years professional experience, including patient care. She has held several global safety positions at Guidant, Abbott (multiple divisions like Vascular, Diagnostics, and Established Pharma), and AbbVie Inc. She currently serves as the working group chair of the Combination Product Coalition's Post-marketing Safety Reporting team.

Patrick M. Caubel, MD, PhD, MBA

Patrick M. Caubel, MD, PhD, MBA

Chief Safety Officer, Pfizer Inc, United States

Patrick Caubel is Chief Safety Officer and Global Head of Worldwide Safety for Pfizer . Patrick earned his M.D. degree, with specialization in Gynecology, Obstetrics and Oncology, from the University of Paris XIII (France), followed by a Ph.D. in Clinical and Experimental Pharmacology from the University of Paris VII (France) and later a M.B.A from Rutgers University. He worked in positions of increasing responsibility first in academia, and subsequently for Merck KgaA, Johnson & Johnson and Sanofi. Pfizer Worldwide Safety is in charge of safety monitoring and reporting for all Pfizer products around the globe. Patrick has been actively involved in COVID vaccine and antivirals development and safety monitoring during the COVID-19 pandemic.

David John Lewis, PhD

David John Lewis, PhD

Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland

Dr Dave Lewis is Visiting Professor of Pharmacovigilance within the School of Life and Medical Sciences at the University of Hertfordshire, UK. Dave worked for over forty years in Patient Safety and Pharmacovigilance at GSK, Shire and Novartis. He was an active contributor to the ICH E2B (electronic reporting) and E2D (post-marketing data management) Expert Working Groups. He led the Innovative Medicines Initiative WEB-RADR project focusing on pharmacovigilance and social media, and was Co-Lead for Work Package 2 of the IHI ConcePTION project, researching pharmacovigilance in pregnancy and breastfeeding. PUBLICATIONS: Bibliography of ~40 publications on pharmacovigilance can be provided upon request.

Rory  Littlebury

Rory Littlebury

Safety Governance Director, GSK, United Kingdom

Rory has over ten years’ experience working at the MHRA, and two years working at GSK in Safety Governance. Rory’s experience includes engagement with a variety of stakeholders, from multi-national pharma companies to healthcare professionals and patients, giving a well-rounded view of the difficulties and challenges faced by those in, or affected by, the regulations of pharmaceuticals.

Elke  Stahl, PhD

Elke Stahl, PhD

Senior Expert, Clinical Trials Department, Federal Institute For Drugs and Medical Devices (BfArM), Germany

Dr. Elke Stahl, Clinical Trial Unit BfArM, Germany. Clinical Trials Senior Expert. CoChair of the Clinical Trial Facilitation Group (CTFG) till 2022. Involved in EMA’s EU CTIS groups as BfArM’s representative, National Contact Point for the CTR in Germany, representative in European Commissions CT working groups. Prior BfArM 10 years experiences as a pharmacokineticist at Bayer HealthCare AG, Germany, in early research up to candidate selection. PostDoc at Hoffmann-La Roche Inc and University of North Carolina (UNC). Ph.D. in pharmacology and licenced pharmacist.

Valerie  Strassmann, PhD, RPh

Valerie Strassmann, PhD, RPh

Scientific Administrator, Data Analytics and Methods Task Force, European Medicines Agency (EMA), Netherlands

Valerie Strassmann is a pharmacist holding a PhD in Pharmacology. From 2010 to 2013 she worked at the Federal Institute for Drugs and Medical Devices (BfArM) in Germany as Pharmacovigilance Assessor. From 2013 to 2019 she was Head of the Department 'Post-Authorisation Safety Studies, Pharmacovigilance Centres, Pharmacoepidemiology' at BfArM. Since September 2019 she works as Seconded National Expert at the European Medicines Agency (EMA).

Belen  Granell Villen

Belen Granell Villen

Quality and Safety Policy Executive (MRPharmS), The Association of the British Pharmaceutical Industry (ABPI), United Kingdom

Soon after qualifying in Spain as a pharmacist, Belen moved to the UK to gain experience and develop an awareness of the procedures in place in hospitals. During the 6 years of work as a hospital pharmacist in the West Midlands, Belen provided award-based medicines management pharmacy service that covered many therapeutic areas. In parallel, she also completed a Postgraduate Diploma in Clinical Pharmacy with commendation at the Queen’s University of Belfast. Belen then moved to London to work as clinical editor at the British National Formulary (BNF). And in 2016 when the opportunity came up, she started a new role at the ABPI in the life science policy area. Her current areas of work are within quality and mainly the safe use of medicines.

Syed  Muntasir

Syed Muntasir

Medical Health Services Executive, TÜV SÜD Ltd, United Kingdom

Catrinel  Popescu, DVM

Catrinel Popescu, DVM

Head, Safety Surveillance and Aggregate Reports, Biogen, United Kingdom

Inge  Zomerdijk, MSc

Inge Zomerdijk, MSc

Pharmacovigilance Assessor, Medicines Evaluation Board (MEB), Netherlands

Inge Zomerdijk has been in the pharmacovigilance department of MEB since 2010. A senior pharmacovigilance assessor and as a regulator has experiences in assessing Risk Management Plans, study protocols and results of evaluations of risk minimisation measures, national implementation of risk minimization measures as well as benefit-risk assessments of both new drug applications or post marketing follow up. In 2015 she completed her PhD research at the Erasmus Medical Center, focusing on how to evaluate risk minimization measures, the impact of these measures on the benefit-risk balance of drugs and translating possibilities and challenges to practical implications for regulatory authorities and industry and remains involved in research.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。